Literature DB >> 6234327

DNA-anti-DNA immune complexes. Antibody protection of a discrete DNA fragment from DNase digestion in vitro.

W Emlen, R Ansari, G Burdick.   

Abstract

We examined the ability of DNase I to digest DNA that was contained with DNA-anti-DNA immune complexes. IgG isolated from the sera of 20 patients with systemic lupus erythematosus (SLE) and containing antibodies to DNA was incubated with double-stranded DNA to form immune complexes. Excess DNase was added, and digestion of DNA was monitored by the conversion of DNA to TCA soluble products. IgG from 8 of the 20 SLE patients protected DNA from degradation by DNase in direct proportion to the amount of DNA bound to IgG as measured in the Farr binding assay. Using IgG from these sera, we showed that the DNA protected from degradation remained bound to IgG during digestion and was 35-45 base pairs in size. The size of this fragment is the same as that which has been proposed to be the minimal size necessary for monogamous bivalent binding of IgG to DNA. We therefore compared the ability of F(ab')2 and Fab' to protect DNA from DNase digestion and demonstrated that the bivalent F(ab')2 fragments were protective, but that the univalent Fab' fragments were not. These results suggest that some antibodies to DNA that bind to DNA via monogamous bivalent binding can protect a 35-45-base pair DNA fragment from DNase digestion. The implications of this finding are discussed with regard to the in vivo behavior and potential pathogenicity of small DNA-anti-DNA immune complexes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6234327      PMCID: PMC425199          DOI: 10.1172/JCI111400

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  Role of DNA-anti-DNA complexes in the immunopathogenesis of tissue injury in systemic lupus erythematosus.

Authors:  J B Winfield; D Koffler; H G Kunkel
Journal:  Scand J Rheumatol Suppl       Date:  1975

2.  Immunology of DNA. V. Analysis of DNA/anti-DNA complexes.

Authors:  L A Aarden; E R De Groot; F Lakmaker
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

3.  Sequence of the PR promoter of phage lambda.

Authors:  A Walz; V Pirrotta
Journal:  Nature       Date:  1975-03-13       Impact factor: 49.962

4.  Immunology of DNA. IV. Quantitative aspects of the Farr assay.

Authors:  L A Aarden; F Lakmaker; E R De Groot
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

5.  T4 DNA polymerase.

Authors:  I R Lehman
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

6.  Solubility and dialysis limits of DNA oligonucleotides.

Authors:  J E Cleaver; H W Boyer
Journal:  Biochim Biophys Acta       Date:  1972-03-14

7.  Saturation of the reticuloendothelial system with soluble immune complexes.

Authors:  A O Haakenstad; M Mannik
Journal:  J Immunol       Date:  1974-05       Impact factor: 5.422

8.  The clearance and localization of nucleic acids by New Zealand and normal mice.

Authors:  T M Chused; A D Steinberg; N Talal
Journal:  Clin Exp Immunol       Date:  1972-12       Impact factor: 4.330

9.  Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus.

Authors:  E M Tan; P H Schur; R I Carr; H G Kunkel
Journal:  J Clin Invest       Date:  1966-11       Impact factor: 14.808

10.  DNA:anti-DNA complexes: their detection in systemic lupus erythematosus sera.

Authors:  R J Harbeck; E J Bardana; P F Kohler; R I Carr
Journal:  J Clin Invest       Date:  1973-04       Impact factor: 14.808

View more
  15 in total

1.  Cationic and high affinity serum IgG anti-dsDNA antibodies in active lupus nephritis.

Authors:  R Suenaga; N I Abdou
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

2.  Rapid clearance of the lupus antigen Sm is delayed by autoantibody: a possible mechanism of autoimmunity perpetuation.

Authors:  M Field; R D Melsom; F M Brennan; D G Williams; L Schreiber; D A McCarthy; R N Maini; R D Nelsom
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

Review 3.  Origins of anti-DNA autoantibodies.

Authors:  R S Schwartz; B D Stollar
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

4.  Hepatic binding of DNA is mediated by a receptor on nonparenchymal cells.

Authors:  W Emlen; A Rifai; D Magilavy; M Mannik
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

5.  Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis.

Authors:  Abdul Hakkim; Barbara G Fürnrohr; Kerstin Amann; Britta Laube; Ulrike Abu Abed; Volker Brinkmann; Martin Herrmann; Reinhard E Voll; Arturo Zychlinsky
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

6.  Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q.

Authors:  S Uwatoko; M Mannik
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

7.  Pharmacodynamics of recombinant human DNase I in serum.

Authors:  W S Prince; D L Baker; A H Dodge; A E Ahmed; R W Chestnut; D V Sinicropi
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

8.  Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury.

Authors:  Xiaoping Qing; Milena Pitashny; David B Thomas; Franck J Barrat; Mark P Hogarth; Chaim Putterman
Journal:  Immunol Lett       Date:  2008-09-24       Impact factor: 3.685

9.  Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone.

Authors:  P M Rumore; C R Steinman
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

10.  Detection of glomerular-binding immune elements in murine lupus using a tissue-based ELISA.

Authors:  K Bernstein; D Bolshoun; G Gilkeson; T Munns; J B Lefkowith
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.